Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Menter

Showing results (81-90 of 117) with videos related to

Pageof 12
Sort By:
Clinical and Experimental Dermatology|September 9, 2014
The prevalence of Dupuytren contractures in patients with psoriasisM Patel, N R Freeman, S Dhaliwal, et al.
The British Journal of Dermatology|October 10, 2017
No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasisB E Strober, R G B Langley, A Menter, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 18, 2007
Psoriasis: consensus on topical therapiesP C M van de Kerkhof, J Barker, C E M Griffiths, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 23, 2020
Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studiesB Strober, A Menter, C Leonardi, et al.
Human Molecular Genetics|September 5, 2001
Insights into psoriasis and other inflammatory diseases from large-scale gene expression studiesA M Bowcock, W Shannon, F Du, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 21, 2020
Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 studyM A Menter, G J Murakawa, H Glover, et al.
The British Journal of Dermatology|July 17, 2008
Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasisS R Feldman, A B Gottlieb, M Bala, et al.
The British Journal of Dermatology|April 2, 2014
Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)A B Kimball, C Leonardi, M Stahle, et al.
The British Journal of Dermatology|January 23, 2016
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasisK A Papp, M A Menter, M Raman, et al.
Archives of Dermatology|February 1, 1990
Comparative study of 5% permethrin cream and 1% lindane lotion for the treatment of scabiesM W Schultz, M Gomez, R C Hansen, et al.
Pageof 12

Showing results (81-90 of 117) with videos related to

Sort By:
Pageof 12
Clinical and Experimental Dermatology|September 9, 2014
The prevalence of Dupuytren contractures in patients with psoriasisM Patel, N R Freeman, S Dhaliwal, et al.
The British Journal of Dermatology|October 10, 2017
No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasisB E Strober, R G B Langley, A Menter, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 18, 2007
Psoriasis: consensus on topical therapiesP C M van de Kerkhof, J Barker, C E M Griffiths, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 23, 2020
Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studiesB Strober, A Menter, C Leonardi, et al.
Human Molecular Genetics|September 5, 2001
Insights into psoriasis and other inflammatory diseases from large-scale gene expression studiesA M Bowcock, W Shannon, F Du, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|May 21, 2020
Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 studyM A Menter, G J Murakawa, H Glover, et al.
The British Journal of Dermatology|July 17, 2008
Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasisS R Feldman, A B Gottlieb, M Bala, et al.
The British Journal of Dermatology|April 2, 2014
Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR)A B Kimball, C Leonardi, M Stahle, et al.
The British Journal of Dermatology|January 23, 2016
A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasisK A Papp, M A Menter, M Raman, et al.
Archives of Dermatology|February 1, 1990
Comparative study of 5% permethrin cream and 1% lindane lotion for the treatment of scabiesM W Schultz, M Gomez, R C Hansen, et al.
Pageof 12